Onco Filtration

Onco Filtration is a private oncology-focused medical device company developing a proprietary blood filtration system intended to capture and remove circulating tumor cells from large volumes of whole blood. Its core platform, Onco Capture, is described by the company as a patented crossflow filtration technology that can process far larger blood volumes than conventional circulating tumor cell approaches, with potential applications in cancer diagnosis and treatment. The company appears to be focused on solid tumors and positions its technology as both a diagnostic-enabling and potentially therapeutic oncology platform. Publicly available information indicates the business remains private and operational, although it has also been named in a January 15, 2026 SEC enforcement action alleging investor fraud by its founder and affiliated entities. No evidence of marketed products, active clinical trials, or regulatory approvals was identified.